Barclays PLC Acquires 72,591 Shares of Liquidia Co. (NASDAQ:LQDA)

Barclays PLC increased its holdings in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 265.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 99,984 shares of the company's stock after purchasing an additional 72,591 shares during the period. Barclays PLC owned approximately 0.12% of Liquidia worth $999,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new position in Liquidia during the second quarter worth approximately $27,000. Clear Harbor Asset Management LLC bought a new stake in shares of Liquidia in the third quarter valued at about $100,000. Signaturefd LLC boosted its holdings in Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company's stock valued at $100,000 after purchasing an additional 9,984 shares during the period. Ballentine Partners LLC acquired a new stake in Liquidia during the third quarter worth approximately $110,000. Finally, Whitcomb & Hess Inc. grew its holdings in shares of Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock worth $116,000 after purchasing an additional 1,074 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LQDA. Scotiabank assumed coverage on Liquidia in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Needham & Company LLC reissued a "buy" rating and set a $19.00 target price on shares of Liquidia in a research report on Thursday, January 9th. Lifesci Capital began coverage on Liquidia in a research report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price objective for the company. Finally, Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $25.38.

Liquidia Trading Up 6.9 %

Shares of NASDAQ:LQDA traded up $0.78 during mid-day trading on Wednesday, hitting $12.14. 1,224,607 shares of the company traded hands, compared to its average volume of 769,341. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.99. The stock has a market cap of $1.03 billion, a P/E ratio of -7.45 and a beta of 0.23. The stock has a 50-day moving average price of $11.20 and a two-hundred day moving average price of $11.01.

Insider Buying and Selling

In related news, General Counsel Russell Schundler sold 16,393 shares of the firm's stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the sale, the general counsel now owns 573,478 shares in the company, valued at approximately $6,755,570.84. This trade represents a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now directly owns 1,019,177 shares of the company's stock, valued at $12,005,905.06. This represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,581 shares of company stock worth $864,565. 30.10% of the stock is owned by insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).